1. ALLA AKTIER
  2. NYHETER
  3. NANEXA

Nanexa

Nyheter Nanexa Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Nanexa publishes annual report for 2025

MARKN.

Nanexa AB (publ) today announces that the Annual Report for 2025 has been published and is available on the company's website Nanexa AB - Financial reports.

During the year, Nanexa has made significant progress in the NEX-22 project, where the development of monthly and quarterly formulations of semaglutide demonstrated promising preclinical results in the first quarter of 2026. In December, a licence and option agreement was also signed with Moderna, providing Nanexa with an upfront payment of USD 3 million and the potential to receive up to USD 500 million in milestone payments and future royalty revenues.

“The agreement with Moderna is a breakthrough for our business strategy and confirms the strength of our PharmaShell® technology. At the same time, we have taken important steps within the NEX-22 project, now also including semaglutide, and we see that the project has great market potential,” says David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Tapper Partners AB.

About Nanexa AB (publ)

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.
Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa Annual Report 2025

Datum 2026-03-26, kl 08:01
Källa MFN
Bifogade filer
Nanexa Annual Report 2025